Condition: HGG · High Grade Glioma (III or IV) · High Grade Glioma · Sponsor: Neuregen Therapeutics Co., Ltd.
The primary objective of this study is to determine the safe dose range of NRG-103 in patients and to recommend the dosage for subsequent treatment, while also evaluating the preliminary efficacy and tolerability of the product.
This description comes directly from the study's public registry record.
Chris Wang · +86 186 1657 2030 · wangxiaochen@nrg-therapeutics.com
Always discuss trial participation with your own doctor first.
| Huashan Hospital Affiliated with Fudan University | Shanghai, China | Recruiting |
| Zhongnan Hospital of Wuhan University | Wuhan, China | Recruiting |
| The Second Affiliated Hospital of Air Force Medical University | Xi'an, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07710690